ProMIS Neurosciences at the Guggenheim Securities Conference
ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology firm, is gearing up for its participation in the Guggenheim Securities SMID Cap Biotech Conference, where Neil Warma, the company’s Chief Executive Officer, will lead a fireside chat. This significant event is scheduled for Wednesday, February 5, and sets the stage for a vital conversation regarding new developments in the biotechnology sector.
About ProMIS Neurosciences
ProMIS Neurosciences is committed to innovating in the realm of neurodegenerative diseases. The company focuses on exploring and developing targeted antibody therapeutics aimed at harmful misfolded proteins linked to conditions like Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Their approach leverages a unique thermodynamic computational discovery platform, which is pivotal in identifying disease-specific epitopes on misfolded proteins - a technique valued in the biotechnology industry.
Innovative Therapeutic Development
Among ProMIS's notable projects is PMN310, which is tailored for Alzheimer's disease. PMN310 is a distinguished humanized monoclonal antibody developed with the capability to specifically target toxic A? oligomers while avoiding interactions with plaques or monomers. This specificity is crucial, given that oligomers notoriously drive the progression of Alzheimer's. Recent studies have shown promising outcomes, indicating that PMN310 could support enhanced safety and efficacy in treatment.
Clinical Trial Progress
The journey of PMN310 through the clinical trial process has yielded encouraging results. It has successfully completed a Phase 1a clinical study, and ProMIS has now launched a Phase 1b clinical trial including patients with Alzheimer's. This represents a pivotal step toward potential market entry and approval, aligning with ProMIS’s mission to deliver effective treatments for detrimental neurodegenerative diseases.
Engagement and Future Outlook
As ProMIS Neurosciences continues to advance its clinical programs, the company maintains a focus on strategic engagements and partnerships that could amplify their market presence and scientific impact. Participation in events like the Guggenheim Securities Conference allows them to showcase their innovations and connect with key stakeholders, investors, and fellow biotech enterprises.
Company Contact Information
For more details or inquiries, ProMIS Neurosciences can be contacted through Precision AQ, formerly known as Stern IR. Anne Marie Fields, Managing Director, is available at 212-362-1200 for investor relations matters. Furthermore, direct inquiries can be made through info@promisneurosciences.com.
Frequently Asked Questions
What is the focus of ProMIS Neurosciences?
ProMIS Neurosciences is dedicated to developing antibody therapeutics aimed at neurodegenerative diseases such as Alzheimer's, ALS, and MSA.
Who will represent ProMIS at the conference?
Neil Warma, the CEO of ProMIS Neurosciences, will represent the company during a fireside chat at the conference.
What product is ProMIS currently developing for Alzheimer's?
PMN310 is ProMIS's lead product candidate that targets toxic A? oligomers associated with Alzheimer's disease.
What stage is PMN310 currently in?
PMN310 has completed a Phase 1a clinical study and has initiated a Phase 1b clinical trial.
How can I get in touch with ProMIS for more information?
For inquiries, you can reach ProMIS Neurosciences via email at info@promisneurosciences.com or contact their investor relations through Anne Marie Fields at 212-362-1200.
